Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Iclusig (ponatinib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Biologix Pharma, Endo, Incyte, Otsuka, Pint Pharma, Specialised Therap, Takeda

Drug class:

Multi-tyrosine kinase inhibitor

Related drugs:

‹

›

BCR-ABL1 T315I	Chronic Myeloid Leukemia	BCR-ABL1 T315I	Chronic Myeloid Leukemia	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1
BCR-ABL1 T315I	Acute Lymphocytic Leukemia	BCR-ABL1 T315I	Acute Lymphocytic Leukemia	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1
No biomarker	Chronic Myeloid Leukemia	No biomarker	Chronic Myeloid Leukemia	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1
BCR-ABL1 fusion	Acute Lymphocytic Leukemia	BCR-ABL1 fusion	Acute Lymphocytic Leukemia	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1
ABL1 T315I	Chronic Myeloid Leukemia	ABL1 T315I	Chronic Myeloid Leukemia	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1
ABL1 T315I	Acute Lymphocytic Leukemia	ABL1 T315I	Acute Lymphocytic Leukemia	ponatinib Sensitive: A2 - Guideline ponatinib Sensitive : A2	ponatinib Sensitive: A2 - Guideline ponatinib Sensitive : A2
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	ponatinib Sensitive: A2 - Guideline ponatinib Sensitive : A2	ponatinib Sensitive: A2 - Guideline ponatinib Sensitive : A2
No biomarker	Gastrointestinal Stromal Tumor	No biomarker	Gastrointestinal Stromal Tumor	ponatinib Sensitive: A2 - Guideline ponatinib Sensitive : A2	ponatinib Sensitive: A2 - Guideline ponatinib Sensitive : A2
BCR-ABL1 fusion	Chronic Myeloid Leukemia	BCR-ABL1 fusion	Chronic Myeloid Leukemia	ponatinib Sensitive: B - Late Trials ponatinib Sensitive : B	ponatinib Sensitive: B - Late Trials ponatinib Sensitive : B
BCR-ABL1 T315I	B Acute Lymphoblastic Leukemia	BCR-ABL1 T315I	B Acute Lymphoblastic Leukemia	ponatinib Sensitive: C1 - Off-label ponatinib Sensitive : C1	ponatinib Sensitive: C1 - Off-label ponatinib Sensitive : C1
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	ponatinib Sensitive: C2 – Inclusion Criteria ponatinib Sensitive : C2	ponatinib Sensitive: C2 – Inclusion Criteria ponatinib Sensitive : C2
FGFR2 S252W	Endometrial Cancer	FGFR2 S252W	Endometrial Cancer	ponatinib Sensitive: C2 – Inclusion Criteria ponatinib Sensitive : C2	ponatinib Sensitive: C2 – Inclusion Criteria ponatinib Sensitive : C2